ESLA Key Statistics, Chart & Performance
The current stock price of ESLA is 1.45 USD. In the past month the price increased by 2.11%. In the past year, price increased by 29.46%.
ESLA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ESLA. When comparing the yearly performance of all stocks, ESLA is a bad performer in the overall market: 79.04% of all stocks are doing better.
ESLA Financial Highlights
Over the last trailing twelve months ESLA reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -55.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -383.16% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ESLA Forecast & Estimates
7 analysts have analysed ESLA and the average price target is 8.16 USD. This implies a price increase of 462.76% is expected in the next year compared to the current price of 1.45.
ESLA Ownership
ESLA Latest News, Press Relases and Analysis
ESLA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ESLA
Company Profile
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
Company Info
ESTRELLA IMMUNOPHARMA INC
5858 Horton St, Suite 370
Emeryville CALIFORNIA US
Employees: 0
Phone: 15103189098
ESTRELLA IMMUNOPHARMA INC / ESLA FAQ
What does ESTRELLA IMMUNOPHARMA INC do?
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
Can you provide the latest stock price for ESTRELLA IMMUNOPHARMA INC?
The current stock price of ESLA is 1.45 USD. The price increased by 9.85% in the last trading session.
Does ESTRELLA IMMUNOPHARMA INC pay dividends?
ESLA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ESLA stock?
ESLA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the analyst forecast for ESLA stock?
7 analysts have analysed ESLA and the average price target is 8.16 USD. This implies a price increase of 462.76% is expected in the next year compared to the current price of 1.45.
What is the Price/Earnings (PE) ratio of ESTRELLA IMMUNOPHARMA INC (ESLA)?
ESTRELLA IMMUNOPHARMA INC (ESLA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
Would investing in ESTRELLA IMMUNOPHARMA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ESLA.